Bart De Taeye
Directeur/Membre du Conseil chez Aelin Therapeutics NV
Profil
Bart De Taeye is currently the Director at Aelin Therapeutics NV, the Senior Investment Manager at Participatiemaatschappij Vlaanderen NV, a Board Member at Augustine Therapeutics NV, and a Board Member at AstriVax NV.
He obtained his doctorate degree from Katholieke Universiteit Leuven in 2004.
Postes actifs de Bart De Taeye
| Sociétés | Poste | Début |
|---|---|---|
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Private Equity Investor | 01/04/2022 |
Augustine Therapeutics NV
 Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 01/04/2023 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Directeur/Membre du Conseil | 01/09/2022 |
AstriVax NV
 AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Directeur/Membre du Conseil | 01/07/2022 |
Formation de Bart De Taeye
| Katholieke Universiteit Leuven | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Finance |
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Health Services |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
AstriVax NV
AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Health Technology |
